Skip to content

Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors

Added Benefit of Speckle Tracking Echo to Molecular Expression of High Sensitive Troponin I and Cardiac Ryanodine Receptor in Early Detection of Cardiomyopathy in Patients Receiving Anthracycline Chemotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03381014
Enrollment
50
Registered
2017-12-21
Start date
2018-01-01
Completion date
2019-08-01
Last updated
2017-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Effect

Brief summary

Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy. Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs. To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy

Detailed description

Anthracycline chemotherapy has saved the lives of many cancer victims during the 50 years after their discovery.These patients are prone to higher risk of cardiovascular death than the risk of tumor recurrence, particularly in childhood cancer survivors in whom the cardiac mortality rate is seven fold higher. Cardiac toxicity remains an important side effect of anticancer therapies, leading to increased mortality due to mainly heart failure, but also arrhythmias, hypertension, thromboembolism. The time from early development of cardiac dysfunction to the modification or end of chemotherapy and beginning of heart failure therapy, is an important determinant of the extent of recovery. The Cardiotoxicity of anthracyclines may be acute, early or late. A recent study involving 2625 patients (mean follow-up 5 years); showed a 9% overall incidence of Cardiotoxicity after anthracycline treatment, 98% of cases occurred within the first year and were asymptomatic. Cardiotoxicity has been defined using various classifications. Recent guidelines suggest that Cancer therapeutics-related cardiac dysfunction (CTRCD) is defined as a decrease in the LVEF (by echocardiography) of \>10 percentage points to a value below the lower limit of normal. Echocardiography should be repeated before every next administration of anthracycline, after 3, 6, and 12 months from the end of therapy with anthracycline but...Not all patients treated with chemotherapy require such frequently repeated LVEF monitoring as suggested by the guidelines because of the negative impact on patient management and cost-effectiveness ratio for the national health system. Speckle-tracking echocardiography is a noninvasive ultrasound imaging technique that allows for early an objective and quantitative evaluation of global and regional myocardial function. New elevation of serum troponin detected with high sensitivity Troponin assays in patients receiving anthracyclines also predicts subsequent LV dysfunction. Ryanodine receptors (RyRs) are a class of intracellular calcium channels in various forms of excitable tissues like muscles and neurons. In heart failure the RyR2 channels become abnormally active or leaky and are unable to remain closed during diastole. This leads to an increase in spontaneous Ca+2 spark frequency and dysregulated Ca+2 handling within the cardiomyocyte, resulting in decreased systolic contraction and irregular contractile activity.

Interventions

DRUGChemotherapy, Cancer, Anthracyclines

follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* all Newly diagnosed cancer patients with who will receive Anthracycline based regimen chemotherapy

Exclusion criteria

* Insufficient ultrasound image quality, defined as more than three LV segments being suboptimally visualized by conventional echocardiography. * Valvular heart disease * Hypertensive heart disease * Cardiomyopathy * Chronic renal failure * Chronic obstructive air way disease (COPD)

Design outcomes

Primary

MeasureTime frameDescription
early detection of cardiomyopathyabout one yearusing speckle tracking echo to early diagnosis of cardiomyopathy
identify patients whose at risk to develop cardiomyopathyabout one yearUsing the high sensitive troponin with quantitative measurements as biomarker.

Secondary

MeasureTime frameDescription
molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathysame time frame ... about one yearquantitative correlation between the troponin genes and ryanodine receptor in early cardiomyopathy

Contacts

Primary ContactMostafa M Morsy, MD
Mostafa_corono@yahoo.com+201096955959
Backup ContactHatem A helmy, MD
hatem19652007@yahoo.com+201005212162

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026